Source comparison
Best KPV Dosage Crohn's Support 2026: Clinical Evidence Comparison
Clinical data on KPV for inflammatory bowel disease remains limited to pilot studies and case series. No Phase 3 randomised controlled trials exist as of 2026. The following table summarises the most cited protocols and their reported outcomes. | Study / Proto
This comparison does not assign a generated winner or score.
- Clinical data on KPV for inflammatory bowel disease remains limited to pilot studies and case series. No Phase 3 randomised controlled trials exist as of 2026. The following table summarises the most cited protocols and their reported outcomes.
- | Study / Protocol | Dose & Route | Duration | Population | Outcome Measure | Result | Professional Assessment ||—|—|—|—|—|—|| Inflammatory Bowel Diseases 2022 pilot | 1mg SC daily | 6 weeks | 18 Crohn's patients (CDAI 150–300) | Mean CDAI reduction | −92 points (vs −14 placebo) | Modest effect size comparable to mesalamine; small sample limits generalisability || Peptides 2023 case series | 500mcg SC 5×/week | 12 weeks | 8 Crohn's patients in remission | Faecal calprotectin, CDAI maintenance | 6/8 maintained calprotectin <100 mcg/g | Suggests maintenance potential; no control group weakens conclusions || Patient-directed protocol (anecdotal) | 1.5–2mg SC daily (flare); 500mcg (maintenance) | Variable | Observational reports from online communities | Subjective symptom improvement | Faster symptom relief reported at higher initial doses | Uncontrolled data; useful for hypothesis generation but not clinical recommendation || Oral KPV (encapsulated) | 5mg oral daily | 8 weeks | 12 IBD pa